CBAY - CymaBay Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.74
-0.11 (-0.79%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close13.85
Open13.83
Bid13.63 x 800
Ask15.00 x 900
Day's Range13.33 - 14.09
52 Week Range5.00 - 15.59
Volume1,474,685
Avg. Volume1,128,742
Market Cap807.483M
Beta2.93
PE Ratio (TTM)N/A
EPS (TTM)-0.95
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018

    CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, will host an analyst and investor day on June 26, 2018 from 12:00pm to 2:00pm Eastern Time in New York City. Members of CymaBay’s senior management team will provide an update on the company's clinical development of seladelpar in patients with primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). The meeting will also feature presentations by prominent liver experts Dr. Christopher Bowlus, UC Davis Health, Dr. Stephen Harrison, Pinnacle Clinical Research, and Dr. Gideon Hirschfield, University of Birmingham, UK, who will discuss their perspectives on current and novel approaches to treating PBC and NASH.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CBAY earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 CymaBay Therapeutics Inc Earnings Call

  • ACCESSWIRElast month

    Wired News – CymaBay Therapeutics Starts Phase-2b Clinical Trials of Seladelpar for Treatment of Patients with Non-Alcoholic Steatohepatitis

    LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on CymaBay Therapeutics, Inc. (NASDAQ: CBAY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CBAY as the Company's latest news hit the wire. On May 08, 2018, the Company announced the initiation of Phase-2b proof of concept clinical trials of seladelpar for the treatment of patients with non-alcoholic steatohepatitis (NASH). The Company started the Phase-2b study with the screening of patients for the clinical trials.

  • GlobeNewswire2 months ago

    CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update

    CymaBay Therapeutics, Inc. (CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the quarter ended March 31, 2018. “We’ve had an eventful start to the year with the achievement of significant clinical and operational milestones thus far in 2018,” said Sujal Shah, President and Chief Executive Officer of CymaBay. “Having strengthened our balance sheet with a successful financing early in the first quarter, our teams have been singularly focused on advancing seladelpar in both primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH).

  • GlobeNewswire2 months ago

    CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis

    CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it began screening of patients for a phase 2b proof of concept study of seladelpar for the treatment of non-alcoholic steatohepatitis (NASH). NASH, a disease linked to the metabolic syndrome which is associated with obesity and diabetes, is a growing global concern for which no treatment is currently approved. The disease is manifested by the accumulation of fat in the liver that leads to chronic liver inflammation and ultimately to fibrosis and cirrhosis.

  • GlobeNewswire2 months ago

    CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8

    NEWARK, Calif., May 01, 2018-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within CymaBay Therapeutics, IAC/InterActiveCorp, Axcelis Technologies, La Quinta, Hornbeck Offshore Services, and Sprouts Farmers Market — Future Expectations, Projections Moving into 2018

    NEW YORK, April 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Analysts’ Ratings for Achaogen and Peers in April 2018
    Market Realist2 months ago

    Analysts’ Ratings for Achaogen and Peers in April 2018

    Achaogen (AKAO), a late-stage biopharmaceutical company, develops and commercializes antibacterial treatments for MDR (multidrug-resistant) gram-negative infections. Its lead product candidate, plazomicin, targets serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, which was identified as a “nightmare bacteria” by the Centers for Disease Control and Prevention in 2013. Of the 12 analysts covering Achaogen in April 2018, five have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “sell.” The mean rating for the stock is 1.8, and its target price is $21.56.

  • How Has CymaBay Therapeutics Performed Financially?
    Market Realist2 months ago

    How Has CymaBay Therapeutics Performed Financially?

    CymaBay Therapeutics’ (CBAY) MBX-2982 is under evaluation as a novel therapeutic agent. The company has yet to disclose its target indication. The drug was synthesized as a GPR119 agonist and is shown to increase glucose-dependent insulin secretion in animal models and in vitro. Non-clinical studies have shown MBX-2982 to have desirable effects on blood glucose levels.

  • Exploring CymaBay’s Other Promising Product Candidates
    Market Realist2 months ago

    Exploring CymaBay’s Other Promising Product Candidates

    CymaBay Therapeutics’ (CBAY) second product candidate, arhalofenate, is being developed for the treatment of gout. The drug has been studied in five phase two clinical trials in patients suffering from gout and has consistently demonstrated reduction of gout flares and serum uric acid (or sUA). Gout flares are recurring and painful episodes of joint inflammation.

  • Key Updates on CymaBay’s Lead Product Candidate
    Market Realist2 months ago

    Key Updates on CymaBay’s Lead Product Candidate

    CymaBay Therapeutics (CBAY) is currently developing seladelpar for treating primary biliary cholangitis (or PBC), which is an autoimmune disease that causes progressive destruction of the bile ducts in the liver. The company also plans to develop seladelpar for treating non-alcoholic steatohepatitis (or NASH). NASH is a serious chronic liver disease caused by excessive fat accumulation in the liver, which results in inflammation and cellular injury that can progress to fibrosis and cirrhosis and potentially liver failure.

  • What Analysts Recommend for CymaBay Therapeutics
    Market Realist2 months ago

    What Analysts Recommend for CymaBay Therapeutics

    CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.

  • ACCESSWIRE2 months ago

    Wired News – CymaBay to Present Positive Results from Phase-2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at the EASL Liver Meeting 2018

    Stock Monitor: Can-Fite BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on CymaBay Therapeutics, Inc. (NASDAQ: ...

  • CymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% Higher
    Zacks2 months ago

    CymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% Higher

    CymaBay Therapeutics (CBAY) was a big mover last session, as the company saw its shares rise more than 11% on the day.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Keryx Biopharmaceuticals and CymaBay Therapeutics

    NEW YORK, NY / ACCESSWIRE / April 12, 2018 / Biotech stocks Keryx and CymaBay were both flying higher in Wednesday trading on positive news. Keryx announced that it had received the 2018 Corporate Innovator ...

  • Could This Tiny Biotech Rout Intercept In Liver Disease Drugs?
    Investor's Business Daily2 months ago

    Could This Tiny Biotech Rout Intercept In Liver Disease Drugs?

    CymaBay launched to a month-high Wednesday after unveiling strong data for a liver disease treatment — to the detriment of Intercept which has struggled with its rival drug.

  • GlobeNewswire2 months ago

    CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2018

    Seladelpar maintains potent anti-cholestatic and anti-inflammatory activity and appears safe and well tolerated, with no drug-induced pruritus, through 26 weeks of treatment Results from the extended study ...

  • TheStreet.com2 months ago

    5 Small-Cap Stocks With Explosive Upside Potential

    These five stocks may be small but top analysts see big potential ahead. Here are the names you must know about.

  • ACCESSWIRE3 months ago

    CymaBay Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 15, 2018 / CymaBay Therapeutics, Inc. (NASDAQ: CBAY ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018 at 4:30 PM Eastern ...

  • High Growth Stocks To Invest In
    Simply Wall St.4 months ago

    High Growth Stocks To Invest In

    High growth companies such as Myomo and Cymabay Therapeutics has a positive future outlook in terms of their returns, profitability and cash flows. The prospects of these companies tend toRead More...